Nezglyal
What Nezglyal is used for
Nezglyal is indicated for the treatment of Cerebral Adrenoleukodystrophy (cALD) in males with Adrenoleukodystrophy (ALD) aged 2 to 12 years with non Gadolinium (Gd) enhancing lesions (i.e. Gd negative) in brain Magnetic Resonance Imaging (MRI), with a Neurological Functional Score (NFS) of 0 or 1.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- Approved under exceptional circumstances: full data cannot be collected, usually because the disease is very rare.
Key facts
- Brand
- Nezglyal
- Active substance
- leriglitazone
- Disease area
- Adrenoleukodystrophy
- Medicine group
- Other alimentary tract and metabolism products
- ATC code
- A16AX23
- Marketing authorisation holder
- Minoryx Therapeutics S.L.
- Authorised in the EU since
- 2026
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Nezglyal used for?
Nezglyal is indicated for the treatment of Cerebral Adrenoleukodystrophy (cALD) in males with Adrenoleukodystrophy (ALD) aged 2 to 12 years with non Gadolinium (Gd) enhancing lesions (i.e. Gd negative) in brain Magnetic Resonance Imaging (MRI), with a Neurological Functional Score (NFS) of 0 or 1.
What is the active substance in Nezglyal?
Nezglyal contains leriglitazone.
Who makes Nezglyal?
The EU marketing authorisation holder is Minoryx Therapeutics S.L..
Is Nezglyal an orphan medicine?
Yes. Nezglyal is designated an orphan medicine in the EU, for a rare disease (Adrenoleukodystrophy).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU